Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy
JADE(JADE) First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101
September 2, 2025Clinical Trials
Read more →